New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...

As original Medicare faces funding shortfalls, Dr. Oz may shift to private insurance providers through Medicare Advantage.

Zepbound may not be as widely known as its competitors, but the weight-loss drug may soon be more accessible than the rest.

Medicare, the government-backed program for adults aged 65 and older and those with disabilities, only covers the use of ...

Coverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...

Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...

Medicare Part D spending for 10 selected diabetes drugs totaled more than $35.8 billion in 2023, a 364% increase from 2019, according to a new data brief from the Department of Health and Human Servic ...

Opinion: It’s time we prioritize innovation and invest in solutions that truly address the root cause of this chronic and ...

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...

Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a five-year period and could ...